Abiopharma

🔍 Jackson Andrew C. (Executive)

Company: Calidi Biotherapeutics, Inc. (CLDI)

Report Date: 2026-08-17

Detailed Transactions and Holdings:

• Acquired 14,000 shares of Stock Options (right to buy) at $1.36 per share (Derivative)
  Date: 2026-08-17 | Code: A | Expires: 2036-08-17 | Exercise: 2026-08-17 | equity_swap_involved: 0 | shares_owned_after: 14,000.00 | transaction_form_type: 4 | Footnotes: F1, F2

Footnotes:

• F1: Pursuant to the Issuer's 2023 Equity Incentive Plan (the "2023 Plan"), on August 17, 2026 (the "Grant Date"), the Reporting Person was granted 14,000 incentive stock options (the "Options") at an exercise price of $1.36, which is equal to the closing price of the Issuer's common stock on the Grant Date. 25% of the options will vest upon the one (1) year anniversary of 08/17/2026, and the remaining 75% of the options will vest in 1/36th installments on a monthly basis, subject to the Reporting Person's continued service to the Issuer. The Options were granted in a transaction exempt under Rule 16b-3 to the Reporting Person.
• F2: Does not include the incentive stock options previously granted to the Reporting Person.